Nurix Therapeutics and Roche forge $2.3B global collaboration
Nurix Therapeutics (NASDAQ:NRIX) announced on June 8, 2026, that it has entered into a global licensing and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg (NX-5948).
The deal, which leverages Nurix’s expertise in targeted protein degradation and Roche’s extensive global clinical and commercial infrastructure, is valued at up to $2.3 billion in potential payments.
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and remains eligible for subsequent development, regulatory, and sales milestones.
The collaboration encompasses a broad clinical development program targeting B-cell malignancies, immunology, and neurology, including plans for Phase 2 and Phase 3 trials in indications such as chronic lymphocytic leukemia (CLL), multiple sclerosis, and chronic spontaneous urticaria.
The financial structure of the partnership includes a shared commitment to global development, with costs divided 60% by Roche and 40% by Nurix.
In the United States, the two companies will co-commercialize the drug and share profits and losses on an equal 50/50 basis.
Outside of the U.S., Roche will lead commercialization efforts, with Nurix receiving tiered royalties ranging from the low- to high-teens.
Bexobrutideg is an investigational, orally bioavailable, brain-penetrant BTK degrader.
Unlike traditional BTK inhibitors that merely block kinase activity, bexobrutideg harnesses the body’s natural protein disposal system to eliminate the BTK protein entirely.
This mechanism is designed to overcome resistance mutations that often emerge with standard-of-care therapies, potentially offering a best-in-class profile for patients with complex blood cancers and immune-mediated diseases.
The transaction is subject to customary closing conditions, including regulatory clearances under the Hart-Scott-Rodino Antitrust Improvements Act, and is currently expected to close in the third quarter of 2026.
